• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Technology

The Trader Daily: Let's Welcome Biotechs to the House of Pain

The bulls can show them around the place.
By BOB BYRNE Aug 10, 2015 | 07:00 AM EDT
Stocks quotes in this article: TLT, XLU, SPY, QQQ, DIA, IWM, USO, XBI, XME, FCG, XLE, ACAD, ALNY, OPK, BMRN

Last week was a rough one for bulls. And unless you were aggressively long the iShares 20+ Year Treasury Bond ETF (TLT) or Utilities Select Sector SPDR ETF (XLU), you probably endured a few head shots.

From an index standpoint, the SPDR S&P 500 Trust (SPY), Powershares QQQ Trust (QQQ) and SPDR Dow Jones Industrial Average ETF (DIA) declined between 1.2% and 1.65%. The hardest-hit index, the iShares Russell 2000 (IWM), fell nearly 2.5%.

Of the major commodities I track, light crude oil was obviously the week's biggest loser. The United States Oil ETF (USO) declined roughly 6.6%. Those tracking the futures market will note September crude closed at $43.75, a new contract low.

From a sector standpoint, the SPDR S&P Biotech ETF (XBI), SPDR S&P Metals and Mining ETF (XME), First Trust ISE-Revere Natural Gas ETF (FCG) and Energy Select Sector SPDR ETF (XLE) were the week's biggest losers. Given the near-daily declines in oil and metals, I see no need to expound on them further. Biotech, on the other hand, is a newcomer to the house of pain.

A few biotechs particularly hard hit on the week were Acadia Pharma (ACAD), Alnylam Pharma (ALNY), Opko Health (OPK) and BioMarin Pharma (BMRN). Rather than delve into the technicals of each individual stock, just note the XBI closed beneath both its late June and early July swing low, and, for a second consecutive session, beneath its 50-day exponential moving average (EMA).

Before we lay out Monday's trade plan, let's look beneath the surface of the S&P 500.

SPDR S&P 500 Trust (SPY) -- Weekly
View Chart » View in New Window »

For those unclear what they're looking at on the chart above, the top chart is a weekly view of the SPY. Beneath the SPY you'll see the NYAD, which is simply the NYSE advance/decline line. Under the NYAD are two additional indications of market breadth. The first is the percent of S&P 500 stocks trading above their 50-day moving average. And the second is the percent of S&P 500 stocks trading above their 200-day moving average.

As you've probably deduced from the downward sloping red trend lines, we have bearish divergences aplenty (and they've been in place for quite some time). Simply put, the SPY is holding its own at a time when fewer than 50% of S&P 500 stocks are trading above their 50-day moving average. That, frankly, will remain an ongoing problem for the bulls.

Turning our attention to Monday's E-mini S&P 500 Futures (Es) auction, we'll want to continue to treat the 2080 to 2083 area as a major pivot. As long as value (and session closes) remain beneath that three-handle zone, a short-term bearish posture will remain appropriate.

10-Minute S&P Futures Volume Profile
View Chart » View in New Window »

Keeping in mind the Es close on top of Friday's volume point of control (VPOC/Value), any rejection from 2080.50 to 2083 would encourage sellers to target 2073.50 (Friday's value), 2068 and 2057.75.

A sustained shift in value above the low-2080s would improve the picture for bulls, and shift our focus toward 2088.75 and 2097.50.

Any trading or volume profile related questions can be posted in the comments section below, emailed to me at parkcityyeti@gmail.com or posted to my Twitter feed @ByrneRWS

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Byrne had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Technology

More from Technology

China's Moves to Stop Buying U.S. Tech Aren't Going Away - But They Have Limits

Eric Jhonsa
Dec 9, 2019 3:16 PM EST

Beijing is intent on reducing its dependence on American hardware, software and chips. But reducing it and eliminating are two very different things.

The Final 4 Unsightly Stocks Going Into My Next Tax-Loss Selling Portfolio

Jonathan Heller
Dec 9, 2019 12:00 PM EST

We'll track a dozen beaten-up stocks that could be subject to tax-loss selling at the end of 2019 to see whether they can stage comebacks in 2020.

Want a Slice of Apple? You Have Some Options

Bob Lang
Dec 9, 2019 11:00 AM EST

You can buy strategically on dips to avoid getting left holding the bag as prices keep rising.

Time to Take a Risk With Amazon, a Trade With Netflix

Carolyn Boroden
Dec 9, 2019 8:30 AM EST

Here I outline how to play NFLX and AMZN, but the latter comes with a catch.

Here's a Recap of the Small Caps vs. the Large Caps

Helene Meisler
Dec 9, 2019 6:00 AM EST

What just happened last week? Quite a bit, but pay attention to this: For the past two years, the large cap QQQs had been the leaders, but not so lately.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:02 AM EST BOB LANG

    Added Some Peleton

    This stock is starting to gain some traction, the ...
  • 01:06 PM EST CAROLYN BORODEN

    MRK and LVS Targets Coming Up

    View Chart » View in New Window »  LVS View C...
  • 12:01 PM EST BOB LANG

    Rolling Up Apple

    Just the other day we added some Apple calls on th...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2019 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login